



A.S.L. VC

Azienda Sanitaria Locale
di Vercelli

Corso M. Abbiate, 21 – 13100 VERCELLI

Tel. +39 0161 5931 fax +39 0161 210284

www.aslvc.piemonte.it

Posta certificata: aslvercelli@pec.aslvc.piemonte.it

P.I. / Cod. Fisc. 01811110020

Comunicazioni complessive ai sensi della Legge 648/1996

INSERIMENTO

Con Determina AIFA 128842/2018 viene inserita alla specifica sezione una nuova lista, ALLEGATO P10_Novembre 2018, relativa ai *farmaci con uso consolidato nell'ambito delle cure palliative per la popolazione pediatrica*, per indicazioni anche differenti da quelle previste dal provvedimento di autorizzazione all'immissione in commercio.

Il provvedimento è entrato in vigore dal giorno 4.12.2018.


Il testo completo della Determina, pubblicato sulla G.U. n. 281 del 3.12.2018, è consultabile al seguente indirizzo:

http://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2018-12-03&atto.codiceRedazionale=18A07693&elenco30giorni=true

ALLEGATO P10– Novembre 2018

FARMACI CON USO CONSOLIDATO NELLE CURE PALLIATIVE (FASE DI TERMINALITA') IN PEDIATRIA PER INDICAZIONI ANCHE DIFFERENTI DA QUELLE PREVISTE DAL PROVVEDIMENTO DI AUTORIZZAZIONE ALL'IMMISSIONE IN COMMERCIO
FARE RIFERIMENTO AL DOCUMENTO "FARMACI OFF-LABEL IN CURE PALLIATIVE (CP) PER LA POPOLAZIONE PEDIATRICA" www.aifa.gov.it

Nome principio attivo	Indicazione terapeutica off-label	Referenze di letteratura
<p>Butilscopolamina- ioscina butilbromuro</p>	<p>Somministrazione e.v. per ostruzione intestinale da peritonite in pazienti oncologici.</p>	<p><u>Tytgat GN.</u> <i>Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain.</i> Drugs 2007</p> <p><u>Mercadante S. et al.</u> <i>Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review.</i> J Pain Symptom Manage. 2007</p> <p><u>Miller M. and Karwacki M.</u> Management of the gastrointestinal tract in paediatric palliative medicine. OXFORD TEXTBOOK OF PALLIATIVE CARE FOR CHILDREN . Oxford University press 2nd edition 2012.</p>
	<p>Somministrazione e.v per riduzione delle secrezioni e del rantolo nella terminalità.</p>	<p><u>Albert RH.</u> <i>End-of-Life Care: Managing Common Symptoms.</i> Am Fam Physician. 2017</p> <p><u>Miller M. and Karwacki M.</u> Management of the gastrointestinal tract in paediatric palliative medicine. OXFORD TEXTBOOK OF PALLIATIVE CARE FOR CHILDREN . Oxford University press 2nd edition 2012.</p>




Nome principio attivo	Indicazione terapeutica off-label	Referenze di letteratura
Desmedetomidina	Controllo dei sintomi stressanti da patologia o procedura e difficoltà di addormentamento al di fuori della terapia intensiva in pazienti in cure palliative, come trattamento in situazioni non rispondenti alle terapie convenzionali.	<p><u>Mahmoud M. et al</u>, <i>Dexmedetomidine: review, update, and future considerations of paediatric perioperative and peri-procedural applications and limitations</i>. Br J Anaesth. 2015</p> <p><u>Sulton C. et al</u>, <i>Pediatric Procedural Sedation Using Dexmedetomidine: A Report From the Pediatric Sedation Research Consortium</i>. Hosp Pediatr. 2016</p> <p><u>Ni J. et al</u>, <i>Effect of dexmedetomidine on preventing postoperative agitation in children: a meta-analysis</i>. PLoS One. 2015</p> <p><u>Weerink M.A.S. et al</u>, <i>Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine</i>. Clin Pharmacokinet 2017</p> <p><u>Alexopoulou C. et al</u>, <i>Effects of Dexmedetomidine on Sleep Quality in Critically Ill Patients</i>. Anesthesiology 2014</p> <p><u>Cozzi G. et al</u>, <i>Intranasal Dexmedetomidine for Procedural Sedation in Children, a Suitable Alternative to Chloral Hydrate</i>. Paediatr Drugs. 2017</p>
	Via di somministrazione endonasale.	
Fentanile	Uso per via transcutanea, e.v. per la gestione del dolore acuto e/o cronico da patologia oncologica e non oncologica.	<p><u>Collins J.J. et al</u>, <i>Transdermal Fentanyl in children with cancer pain: feasibility, tolerability and pharmacokinetic correlates</i>. J pediatr 1999</p> <p><u>Finkel J.C. et al</u>, <i>Transdermal Fentanyl in the management of children with chronic severe pain</i>. Cancer 2005</p> <p><u>Zernikow B. et al</u>, <i>Transdermal Fentanyl in childhood and adolescence: a comprehensive Literature review</i>. J Pain 2007</p>




<i>Nome principio attivo</i>	<i>Indicazione terapeutica off-label</i>	<i>Referenze di letteratura</i>
		<p><u>Drake R. et al</u>, Pharmacological management. OXFORD TEXTBOOK OF PALLIATIVE CARE FOR CHILDREN . Oxford University press 2006</p>
	<p>Usò trans mucoso per dolore incidente/breakthrough pain/dolore procedurale</p>	<p><u>Zernikow B. et al</u>, <i>Pediatric palliative care: use of opioids for the management of pain</i>. Paediatr Drugs. 2009</p> <p><u>Mystakidou K. et al</u>, <i>Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics</i>. Drug Deliv. 2006</p> <p><u>Friedrichsdorf S.J. et al</u>, <i>Management of breakthrough pain in children with cancer</i>. J Pain Research 2014</p> <p><u>Zeppetella G. et al</u>, <i>Opioids for the management of breakthrough pain in cancer patients</i>. Cochrane Database Syst Rev. 2013</p> <p><u>Drake R. et al</u>, <i>Pharmacological approaches to pain: Simple analgesics and opioids</i>. OXFORD TEXTBOOK OF PALLIATIVE CARE FOR CHILDREN. Oxford University press 2nd edition 2012</p>




Nome principio attivo	Indicazione terapeutica off-label	Referenze di letteratura
Gabapentin	Dolore neuropatico o misto in bambini in cure palliative, di età superiore a 2 anni.	<p><u>Friedrichsdorf S.J. et al</u>, <i>Pain reporting and analgesia management in 270 children with a progressive neurologic, metabolic or chromosomally based condition with impairment of the central nervous system: cross-sectional, baseline results from an observational, longitudinal study.</i> J Pain Res. 2017</p> <p><u>Brown S.C. et al</u>, <i>A randomized controlled trial of amitriptyline versus gabapentin for complex regional pain syndrome type I and neuropathic pain in children.</i> Scandinavian Journal of Pain 2016</p> <p><u>Cooper T.E.</u>, <i>Antiepileptic drugs for chronic non-cancer pain in children and adolescents.</i> Cochrane Database Syst Rev. 2017</p> <p><u>Kaul I. et al</u>, <i>Use of gabapentin and pregabalin for pruritus and neuropathic pain associated with major burn injury: A retrospective chart review.</i> Burns. 2017</p> <p><u>Butkovic D. et al</u>, <i>Experience with gabapentin for neuropathic pain in adolescents: report of five cases.</i> Paediatr Anaesth. 2006</p> <p><u>Mc Cullock R.</u> <i>Pharmacological approaches to pain. 3: Adjuvants for neuropathic and bone pain.</i> OXFORD TEXTBOOK OF PALLIATIVE CARE FOR CHILDREN . Oxford University press 2nd edition 2012.</p>
Ketamina	Gestione del dolore procedurale o neuropatico/misto non rispondente ad altra terapia, da solo o in associazione/sostituzione ad analgesici oppioidi.	<p><u>Bredlau A.L. et al</u>, <i>Oral ketamine for children with chronic pain: a pilot phase 1 study.</i> J Pediatr. 2013</p> <p><u>Bredlau A.L. et al</u>, <i>Ketamine for pain in adults and children with cancer: a</i></p>



Nome principio attivo	Indicazione terapeutica off-label	Referenze di letteratura
		<p>systematic review and synthesis of the literature. Pain Med. 2013</p> <p><u>Tawfic Q.A.</u>, A review of the use of ketamine in pain management. J Opioid Manag. 2013</p> <p><u>Grunwell J.R. et al.</u>, <i>Pediatric Procedural Sedation Using the Combination of Ketamine and Propofol Outside of the Emergency Department: A Report From the Pediatric Sedation Research Consortium</i>. Pediatr Crit Care Med. 2017</p> <p><u>Poonai N. et al.</u>, <i>Intranasal ketamine for procedural sedation and analgesia in children: A systematic review</i>. PLoS One. 2017</p> <p><u>Mehran M. et al.</u>, <i>Effect of Intranasal Sedation Using Ketamine and Midazolam on Behavior of 3-6 Year-Old Uncooperative Children in Dental Office: A Clinical Trial</i>. J Dent (Teheran). 2017</p> <p><u>Scheier E. et al.</u>, <i>Intranasal ketamine proved feasible for pain control in paediatric care and parental support was high</i>. Acta Paediatr. 2017</p> <p><u>Carr D.B. et al.</u>, <i>Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study</i>. Pain. 2004</p>
Ketorolac	Somministrazione orale e sublinguale per un periodo massimo di 5 giorni in soggetti di 4-15 anni di età senza accesso vascolare, per gestione di dolore acuto nocicettivo episodico moderato/severo, quale integrazione di altra analgesia se non efficace.	<p><u>Dancel R. et al.</u>, <i>Acute Pain Management in Hospitalized Children</i>. Rev Recent Clin Trials. 2017</p> <p><u>Plapler P.G. et al.</u>, <i>Double-blind, randomized, double-dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain</i>. Drug Des Devel Ther. 2016</p>




Nome principio attivo	Indicazione terapeutica off-label	Referenze di letteratura
		<p><u>Neri E. et al</u>, <i>Sublingual ketorolac versus sublingual tramadol for moderate to severe post-traumatic bone pain in children: a double-blind, randomised, controlled trial</i>. Arch Dis Child 2013</p> <p><u>Di Massa A. et al</u>, <i>Ketorolac for paediatric postoperative pain. A review</i>. Minerva Anestesiol. 2000</p> <p><u>Marzuillo P. et al</u>, <i>Narrative review shows that the short-term use of ketorolac is safe and effective in the management of moderate-to-severe pain in children</i>. Acta Paediatr 2017</p>
<p>Lidocaina</p>	<p>Uso in aerosol per il trattamento della tosse refrattaria ad altre terapie, in caso di metastasi polmonari.</p>	<p><u>Slaton R.M. et al</u>, <i>Evidence for therapeutic uses of nebulized lidocaine in the treatment of intractable cough and asthma</i>. Ann Pharmacother. 2013</p> <p><u>Decco M.L. et al</u>, <i>Nebulized lidocaine in the treatment of severe asthma in children: a pilot study</i>. Ann Allergy Asthma Immunol. 1999</p> <p><u>Truesdale K. et al</u>, <i>Nebulized lidocaine in the treatment of intractable cough</i>. Am J Hosp Palliat Care. 2013</p> <p><u>Molassiotis A. et al</u>, <i>Symptomatic Treatment of Cough Among Adult Patients With Lung Cancer: CHEST Guideline and Expert Panel Report</i>. Chest. 2017</p>




Nome principio attivo	Indicazione terapeutica off-label	Referenze di letteratura
	<p>Uso endovenoso per il trattamento del dolore neuropatico in pazienti in CPP non rispondenti alle terapie convenzionali.</p>	<p><u>Hutson P. et al.</u>, <i>Intravenous lidocaine for neuropathic pain: a retrospective analysis of tolerability and efficacy.</i> Pain Med. 2015</p> <p><u>Kajiume T. et al.</u>, <i>Continuous intravenous infusion of ketamine and lidocaine as adjuvant analgesics in a 5-year-old patient with neuropathic cancer pain.</i> J Palliat Med. 2012</p>
<p>Midazolam</p>	<p>Uso intranasale per minore invasività e rapidità di somministrazione in assenza di accesso venoso, anche in caso di urgenza in pazienti in CPP di età superiore a 1 mese.</p>	<p><u>Tsze D.S. et al.</u>, <i>Optimal Volume of Administration of Intranasal Midazolam in Children: A Randomized Clinical Trial.</i> Ann Emerg Med. 2017</p> <p><u>Nemeth M. et al.</u>, <i>Intranasal Analgesia and Sedation in Pediatric Emergency Care-A Prospective Observational Study on the Implementation of an Institutional Protocol in a Tertiary Children's Hospital.</i> Pediatr Emerg Care. 2017</p> <p><u>Jain P. et al.</u>, <i>Efficacy and safety of anti-epileptic drugs in patients with active convulsive seizures when no IV access is available: Systematic review and meta-analysis.</i> Epilepsy Res. 2016</p> <p><u>Glauser T. et al.</u>, <i>Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.</i> Epilepsy Curr. 2016</p> <p><u>Chiaretti A. et al.</u>, <i>Intranasal lidocaine and midazolam for procedural sedation in children.</i> Arch Dis Child. 2011</p>



Nome principio attivo	Indicazione terapeutica off-label	Referenze di letteratura
Ondansetron	<p>Uso endovenoso per la gestione di sintomi da distress non doloroso nella fase di terminalità.</p> <p>Controllo della nausea e del vomito in corso di terapia con oppioidi in pazienti in cure palliative in età \geq 6 mesi.</p>	<p><u>Korzeniewska-Eksterowicz A. et al</u>, Palliative sedation at home for terminally ill children with cancer. J Pain Symptom Manage. 2014</p> <p><u>Postovsky S. et al</u>, <i>Practice of palliative sedation in children with brain tumors and sarcomas at the end of life</i>. Pediatr Hematol Oncol. 2007</p> <p><u>Cowan J.D. et al</u>, <i>Terminal sedation in palliative medicine--definition and review of the literature</i>. Support Care Cancer. 2001</p> <p><u>Wolfe J. et al</u>, <i>Textbook of interdisciplinary pediatric palliative care</i>. Elsevier Saunders 2011</p> <p><u>Jitpakdee T. et al</u>, <i>Strategies for preventing side effects of systemic opioid in postoperative pediatric patients</i>. Paediatr Anaesth 2014</p> <p><u>Engelman E. et al</u>, <i>How much does pharmacologic prophylaxis reduce postoperative vomiting in children? Calculation of prophylaxis effectiveness and expected incidence of vomiting under treatment using Bayesian meta-analysis</i>. Anesthesiology 2008</p> <p><u>Gomez-Arnau J.I. et al</u>, <i>Postoperative nausea and vomiting and opioid-induced nausea and vomiting guidelines for prevention and treatment</i>. Rev Exp Anesthesiol Reanim 2010</p> <p><u>Culy C.R. et al</u>, <i>Ondansetron: a review of its use as an antiemetic in children</i>. Paediatr Drugs 2001</p> <p><u>Binstock W. et al</u>, <i>The effect of premedication with OTFC, with or</i></p>



Nome principio attivo	Indicazione terapeutica off-label	Referenze di letteratura
<p>Scopolamina/ ioscina idrobromuro</p>	<p>Trattamento della scialorrea in pazienti in cure palliative e in fine vita.</p>	<p><i>without ondansetron, on postoperative agitation, and nausea and vomiting in pediatric ambulatory patients. Pediatr Anesthesia 2004</i></p> <p><u>Bavikatte G. et al</u>, <i>Management of Drooling of Saliva. BJMP 2012</i></p> <p><u>Mato A. et al</u>, <i>Management of drooling in disabled patients with scopolamine patches. BJCP 2010</i></p> <p><u>Little S.A. et al</u>, <i>An evidence-based approach to the child who drools saliva. Clin Otolaryngology 2009</i></p> <p><u>Táboas-Pereira M.A. et al</u>, <i>Drooling therapy in children with neurological disorders. Rev Neurol. 2015</i></p> <p><u>Jongerius P.H. et al</u>, <i>Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics. 2004</i></p> <p><u>Walshe M. et al</u>, <i>Interventions for drooling in children with cerebral palsy. Cochrane Database Syst Rev. 2012</i></p> <p><u>Chowdhury N.A. et al</u>, <i>Transdermal Scopolamine Withdrawal Syndrome Case Report in the Pediatric Cerebral Palsy Population. Am J Phys Med Rehabil. 2017</i></p> <p><u>Delgado-Charro M.B. et al</u>, <i>Effective use of transdermal drug delivery in children. Adv Drug Deliv Rev. 2014</i></p> <p><u>Miller M. et al</u>, <i>Management of the gastrointestinal tract in paediatric</i></p>



<i>Nome principio attivo</i>	<i>Indicazione terapeutica off-label</i>	<i>Referenze di letteratura</i>
		palliative medicine. OXFORD TEXTBOOK OF PALLIATIVE CARE FOR CHILDREN . Oxford University press 2 nd edition 2012

18A07693

